How Have the Numbers Shaped Up for Orgenesis (NASDAQ:ORGS)

0
140

Earnings results for Orgenesis (NASDAQ:ORGS)

Orgenesis Inc. is estimated to report earnings on 08/06/2021. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. The reported EPS for the same quarter last year was $1.26.

Orgenesis last posted its quarterly earnings data on May 7th, 2021. The reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.27. The firm had revenue of $9.39 million for the quarter. Orgenesis has generated $0.00 earnings per share over the last year and currently has a price-to-earnings ratio of 251.0. Orgenesis has confirmed that its next quarterly earnings report will be published on Thursday, August 5th, 2021. Orgenesis will be holding an earnings conference call on Thursday, August 5th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 919-882-2331 with passcode “42425”.

Analyst Opinion on Orgenesis (NASDAQ:ORGS)

Dividend Strength: Orgenesis (NASDAQ:ORGS)

Orgenesis does not currently pay a dividend. Orgenesis does not have a long track record of dividend growth.

Insiders buying/selling: Orgenesis (NASDAQ:ORGS)

In the past three months, Orgenesis insiders have not sold or bought any company stock. Only 7.22% of the stock of Orgenesis is held by insiders. Only 21.42% of the stock of Orgenesis is held by institutions.

Earnings and Valuation of Orgenesis (NASDAQ:ORGS

The P/E ratio of Orgenesis is 251.00, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 21.18. The P/E ratio of Orgenesis is 251.00, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 39.54. Orgenesis has a P/B Ratio of 2.34. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

More latest stories: here